ADX-914 for Atopic Dermatitis

Recruiting in Palo Alto (17 mi)

+23 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Q32 Bio Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new drug called ADX-914 in adults with moderate to severe Atopic Dermatitis. The drug is given as an injection over a period of a few months. It aims to reduce skin inflammation and improve skin condition.

Eligibility Criteria

Adults over 18 with chronic Atopic Dermatitis for at least 3 years, showing moderate to severe symptoms despite previous treatments. Excluded are those with recent serious infections, other skin conditions, participation in another trial within the last month or so, exposure to live vaccines recently or during the study, TB history, pregnant or breastfeeding women, known allergies to study treatments and those with certain autoimmune diseases.

Inclusion Criteria

I have tried and not responded well to at least one standard skin treatment.

I am over 18 and have had chronic AD for 3+ years, diagnosed by a specific criteria.

My skin condition affects more than 10% of my body and is moderate to severe.

Exclusion Criteria

You have had a serious infection in the past two months or currently have a serious infection.

I am currently using a treatment for atopic dermatitis.

I do not have skin conditions that could affect study results.

+9 more

Participant Groups

The trial is testing ADX-914 against a placebo in adults with moderate to severe Atopic Dermatitis. It's a phase IIa study where participants don't know if they're getting the real medicine or a dummy pill (double-blind), and neither do the doctors (placebo-controlled).

2Treatment groups

Experimental Treatment

Placebo Group

Group I: ADX-914Experimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention